OPTN - OptiNose, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
1.2100
-0.0400 (-3.20%)
At close: 04:00PM EDT
1.2400 +0.03 (+2.48%)
After hours: 05:46PM EDT
Stock chart is not supported by your current browser
Previous close1.2500
Open1.2200
Bid0.0000 x 1300
Ask0.0000 x 800
Day's range1.1800 - 1.2400
52-week range1.1500 - 4.3000
Volume547,771
Avg. volume296,076
Market cap135.467M
Beta (5Y monthly)-0.22
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Optinose to Present at the Jefferies Healthcare Conference

    YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be avail

  • GlobeNewswire

    Optinose Reports First Quarter 2023 Financial Results and Operational Updates

    Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company reports first quarter 2023 XHANCE net revenue of $11.8 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy spe

  • GlobeNewswire

    Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

    The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis which is assigned at approximately 10 million patient visits annually YARDLEY, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused

  • GlobeNewswire

    Optinose Announces Reporting Date for First Quarter 2023 Financial Results

    Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern TimeYARDLEY, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2023 and corporate updates, before market open on Thursday, May 11, 2023. Company to Host Conference CallMembers of the Company’s leadership team will host a confe

  • GlobeNewswire

    Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incen

  • GlobeNewswire

    Optinose to Present at the Needham Virtual Healthcare Conference

    YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will

  • GlobeNewswire

    Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

    Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical

  • GlobeNewswire

    Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

    Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern TimeYARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2022 and corporate updates, before market open on Tuesday, March 7, 2023. Company to Host Conference CallMembers of the Company’s leadership team will host a con

  • GlobeNewswire

    Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion

    YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to request approval of XHANCE as a treatment for chronic rhinosinusitis. XHANCE® (fluticasone propionate) nasal spray is a drug device combination product combining an anti-inflammatory drug wit

  • GlobeNewswire

    Optinose Announces CEO Transition and Business Update

    Ramy Mahmoud, MD, MPH appointed CEO and to the Board of DirectorsYARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a

  • GlobeNewswire

    Optinose Appoints Paul Spence as Chief Commercial Officer

    YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 year

  • GlobeNewswire

    Optinose Announces Departure of Acting Chief Financial Officer

    YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportunity at a privately-held company. Ms. Janis will continue to serve as Acting Chief Financial Officer until her departure on December 30, 2022. Chief Executive Officer Peter Miller stated “On behalf of our enti

  • GlobeNewswire

    Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

    $50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis Revised Note Purchase Agreement Extends Start of Amortization to September 2025 YARDLEY, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today provided corporate updates and announced that CEO Peter Miller will participate in a

  • GlobeNewswire

    Optinose Announces Pricing of Public Offering of Common Stock and Warrants

    YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants to purchase 26,320,000 shares of its common stock at a combined public offering price of $1.90 per share and accompanying warrant, for gross proceeds of approximately $50 million to Optinose, before dedu

  • GlobeNewswire

    Optinose Announces Proposed Public Offering of Common Stock and Warrants

    YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. All shares of common stock and accompanying warrants to be sold in the offering will be sold by Optinose. In addition, Optinose is expected to gra

  • GlobeNewswire

    Optinose Reports Third Quarter 2022 Financial Results and Operational Updates

    Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients Company reports third quarter 2022 XHANCE net revenue of $20.1 million Company expects full year 2022 XHANCE net revenue to be between $74 to $78 million Company expects full year 2022 operating expenses to be between $127 to $131 million

  • GlobeNewswire

    Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

    YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen2 phase 3 clinical trial will be presented at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting in Louisville, Kentucky on November 12, 2022. ReOpen2 was the second of two phase 3 clinical trials in its ReOpen Program which evaluated

  • GlobeNewswire

    Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

    Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern TimeYARDLEY, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2022 and corporate updates, before market open on Thursday, November 10, 2022. Company to Host Conference CallMembers of the Company’s leadership team will h

  • GlobeNewswire

    Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

    Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program Acute exacerbations of chronic sinusitis can lead to doctor visits, antibiotic use, steroid use, surgery, and important morbidity and loss of quality of life There are approximately 10 million outpatient visits for chronic rhinosinusitis per year,antibiotics are prescribed in ≈70% of visits, and chron

  • GlobeNewswire

    Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting

    ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical RhinologyYARDLEY, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen1 phase 3 clinical trial will be presented at the American Rhinologic Society (ARS) 68th Annual Meeting in Philadelphia, Pennsylvania on September 9, 2022. ReOpen1 was the first of two phase 3 cl

  • GlobeNewswire

    Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

    Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis by the end of 2022 Company expects full year 2022 XHANCE net revenue to be between $85 to $92 million Company expects full year 2022 and operating expenses to be between $129 to $134 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE)

  • GlobeNewswire

    Optinose Announces Reporting Date for Second Quarter 2022 Financial Results

    Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern TimeYARDLEY, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2022 and corporate updates, before market open on Thursday, August 11, 2022. Company to Host Conference CallMembers of the Company’s leadership team will host

  • GlobeNewswire

    Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

    XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark ReOpen trials reveals 66% reduction in sinusitis exacerbations (flares) with use of XHANCE 372 mcg for patients with Chronic Sinusitis Chronic sinusitis exacerbations lead to doctor visits, antibiotic use, steroid use, surgery, and important morbidity and loss of quality of life There are approximate

  • GlobeNewswire

    Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

    Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from ReOpen2 indicate patients treated with XHANCE experienced improvement in symptoms and quality of life when compared to patients treated with placebo In pooled data from ReOpen1 and ReOpen2, XHANCE demonstrated a benefit relative to placebo on CT scans in patients with chronic sinusitis without nasal poly

  • GlobeNewswire

    Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

    First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients Conference call and webcast to be held today at 8:30 a.m. Eastern Time YARDLEY, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on p